Related Experiment Video
Updated: Oct 13, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.0K
Therapeutic antibodies under development for SARS-CoV-2
Zetong Ma1, MengMei Zhu1,2, Shuyi Zhang1
1Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
View (Beijing, China)
|November 12, 2021
Summary
Therapeutic antibodies are being developed to combat COVID-19, offering potential treatments against the ongoing pandemic. Research also explores ACE2 recombinant and fusion proteins for therapeutic applications.
Area of Science:
- Virology
- Immunology
- Drug Development
Background:
- The COVID-19 pandemic presents significant global health and economic challenges.
- Despite extensive research, specific antiviral drugs for SARS-CoV-2 remain elusive.
- Antibody-based therapies have a history of success in managing viral epidemics.
Purpose of the Study:
- To summarize current therapeutic antibody strategies against SARS-CoV-2.
- To review research involving ACE2 recombinant protein and ACE2-Ig fusion proteins for COVID-19 treatment.
Main Methods:
- Literature review of therapeutic antibodies targeting SARS-CoV-2.
- Analysis of studies on ACE2-based therapeutic approaches.
Main Results:
- Several antibody drugs against SARS-CoV-2 have advanced into clinical trials.
- These antibody therapies have demonstrated promising therapeutic effects.
- Research into ACE2 recombinant protein and ACE2-Ig fusion proteins is ongoing.
Conclusions:
- Therapeutic antibodies represent a key strategy in the fight against COVID-19.
- Further development and clinical evaluation of antibody drugs and ACE2-based therapies are warranted.
